Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

EAU NMIBC Risk

EAU NMIBCRisk Stratification for Bladder Cancer

Prognostic Grouping

Note: Risk is based on the 2021 EAU criteria which considers tumor stage (Ta vs T1), grade (G1-G3/LG vs HG), number of tumors, and concomitant CIS.

Risk Profile

Low

Management Outlook

Low risk group. Single, primary, low-grade Ta tumor < 3 cm. Surveillance only is typically recommended.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

Patients with biopsy-proven Ta, T1, or CIS bladder cancer.
To determine the schedule for intravesical therapy (e.g., BCG or Mitomycin C).
To identify "Very High Risk" candidates for early radical cystectomy.

How it Works

Risk Variables

Tumor Stage (Ta vs. T1)
Tumor Grade (G1-3 or LG/HG)
Presence of Carcinoma in Situ (CIS)
Number of tumors (Solitary vs. Multiple)
Tumor size (≥ 3 cm)
Prior recurrence rate

EAU Risk Groups

CategoryDefinitionManagement
Low RiskPrimary, solitary, Ta G1 (LG) < 3cm.Immediate post-op Mitomycin; Surveillance.
Intermediate RiskAll cases not in low, high, or very high.Intravesical BCG or Chemo for 1 year.
High RiskT1, or G3 (HG), or CIS.Intravesical BCG for 1-3 years.
Very High RiskT1 G3 with CIS, or multiple T1 G3.Consider early Radical Cystectomy.

Clinical Pearls

The Progression Risk

While recurrence is common in NMIBC, "Progression" (to muscle-invasive disease) is the critical event to prevent. High-risk patients have a ~20% risk of progression within 5 years if treated with BCG, whereas Very High Risk patients may exceed 40%, necessitating a more aggressive surgical approach.

The Evidence

Key Reference

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma in Situ) - 2021 Update

Sylvester RJ et al. • European Urology. 2021;79(4):545-562

Last Comprehensive Review: 2026

Related Tools

EAU NMIBC Risk
ISUP Grade Groups
CTCAE v5.0
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.

Recent Journal Updates

CancerJul 22, 2026
Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Clinical Context

We think this has broad domain relevance to EAU NMIBC Risk Classification.

Cancer MedicineJul 16, 2026
Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA‐Dependent Tumor Immune Microenvironment

Clinical Context

We think this has broad domain relevance to EAU NMIBC Risk Classification.

PLOS MedicineJul 13, 2026
Self-explaining artificial intelligence for the classification of B cell non-Hodgkin lymphoma: A diagnostic decision support study

Clinical Context

We think this might be relevant to the clinical guidance for EAU NMIBC Risk Classification.